Humana ($HUM)

HR8375, the Medicare Advantage Improvement Act of 2026, introduces a 72-hour deadline for prior authorization decisions effective January 2028. The bill is in early legislative stage (sponsor introductory remarks only, April 2026). MA insurers face compliance costs, but the multi-year timeline reduces near-term market disruption. Major MA-exposed insurers like UNH and HUM face the highest absolute operational burden; HUM is most exposed relative to market cap. Real market data shows MA-insurer stocks rallied 15-60% over the last 30 days prior to this bill's introduction, indicating the bill is a manageable headwind rather than a sector-reshaping event at this stage.

This $929 million contract to TriWest Healthcare Alliance, a major VA healthcare provider, signals continued federal investment in veteran health services, potentially benefiting publicly traded managed care organizations that serve similar populations or act as subcontractors.

HR8261, the Chronic Care Management Improvement Act of 2026, is an early-stage House bill eliminating Medicare beneficiary cost-sharing for chronic care management services starting January 2027. With only 2 cosponsors, referral to two committees, and zero direct federal spending, this bill is procedural at this stage. Market impact is minimal near-term; Medicare Advantage insurers and primary care providers with CCM programs are the structural beneficiaries if the bill advances.

HR6610 would mandate NADAC-based reimbursement and point-of-sale rebate passthrough for PBMs in federal employee health plans. The bill is early-stage with 32 cosponsors and bipartisan sponsorship. Direct financial impact on UNH, CI, and HUM is limited to a small book of business, but the legislation signals growing bipartisan appetite for PBM pricing reform that could expand to larger markets.

HR8164 is a procedural bill codifying existing administrative requirements for health insurers regarding medical child support orders. It carries zero new mandates, zero appropriations, and zero financial impact on the healthcare sector. This is market-irrelevant for retail investors.

HR8163 (Provider Reimbursement Stability Act) is an early-stage procedural bill that reduces physician fee cut frequency under Medicare budget neutrality rules, directly benefiting Medicare Advantage insurers. $UNH, $CVS, and $HUM have rallied 3-12% in the past week on bipartisan momentum signals, though zero authorized funding means zero direct revenue impact—only regulatory relief.

HR8129, a bill to create a permanent full risk ACO program in traditional Medicare, is at early legislative stage with low momentum (1 cosponsor, 2 committees). Despite this, the four largest Medicare Advantage insurers ($UNH, $HUM, $CNC, $CVS) have already rallied sharply over 30 days — $CNC +62.34%, $HUM +38.49%, $UNH +35.85%, $CVS +16.05% — indicating investors are pricing in the structural shift to value-based care regardless of this specific bill's passage timeline.

The Living Donor Protection Act of 2025 (S.1552), reported favorably out of committee and on the Senate calendar, prohibits life, disability, and long-term care insurers from discriminating against living organ donors. This removes an underwriting barrier, expands the insured pool, and drives increased transplant volume. Major managed care and insurance stocks have rallied 9-39% in the last 30 days, with this legislation providing a structural tailwind for revenue growth across the sector.

The Insurance Fraud Accountability Act (S.976) imposes new $10k–$50k civil penalties per violation on agents/brokers for fraudulent ACA enrollments. Though still in early committee stage, the bill places compliance burdens on major health insurers operating ACA marketplaces. Recent 30-day rallies of +36% in UNH and +39% in HUM appear disconnected from this specific regulatory risk, suggesting potential sector downside as legislative risk is repriced.

The ANCHOR Act of 2025 (S. 3300) creates a new state option to expand Medicaid eligibility to uninsured adults with serious mental illness or substance use disorder at or below 100% FPL. The bill is in early legislative stages—referred to Senate Finance Committee December 2025. Despite early status, the market is pricing in passage: CNC has rallied +62% in 30 days to $53.11, MOH +46% to $195.22, and HUM +39% to $241.35. Centene, Molina, and Humana are the primary structural beneficiaries due to their outsized Medicaid MCO exposure.

The ACCESS Act expands STLDI to up to 3 years, exempt from ACA essential health benefits and MLR rules, directly benefiting major health insurers. The bill is early-stage with low legislative momentum. Market data shows UNH +36%, HUM +39%, and CI +9% over 30 days, reflecting anticipatory pricing of regulatory relief.

HR6837 is an early-stage House bill imposing ERISA fiduciary duty on pharmacy benefit managers, directly threatening the lucrative rebate retention and spread pricing revenue model for CVS, CI, ELV, UNH, and HUM. Despite the bearish structural impact, the market has priced in a 16–36% rally across these tickers over the past 30 days, reflecting broad skepticism that the bill will pass in its current form. With no companion Senate markup and bipartisan momentum limited (one R cosponsor), passage is a 30–40% probability over the next 12 months. Long-term risk for PBM margins is real but deferred.

Sen. Schumer introduced S. 2556 (Protecting Health Care and Lowering Costs Act) on July 30, 2025. The bill makes permanent the ACA premium tax credit expansion (eliminates the 400% FPL cap, lowers applicable percentages). In early committee stage with 46 Democratic cosponsors, passage odds are low in the divided 119th Congress, but the policy signal is structurally bullish for major ACA market insurers. Real market data shows UNH up 36.28%, HUM up 39.06%, CVS up 16.35%, and CI up 9.19% in the past 30 days — strong momentum driven by the bill's reintroduction reflecting forward pricing on increased subsidized enrollment expectations.

The ACO Assignment Improvement Act of 2025 widens Medicare Shared Savings Program attribution to include NP and PA visits. This directly benefits ACO operators among major Medicare Advantage insurers (UNH, HUM, CVS, CNC, MOH) by expanding their addressable patient pool for shared savings without additional provider recruitment. The bill is at early legislative stage with a bipartisan Senate sponsorship, but the mechanism is structurally favorable for the sector.

HR2148, the Veteran Caregiver Reeducation, Reemployment, and Retirement Act, expands VA medical coverage for family caregivers and creates a transition pipeline into Medicare Advantage. The bill is out of committee and awaiting House floor action with a Senate companion bill (S879) also advancing. Major health insurers (HUM, UNH, ELV, CVS, CI) have rallied 3.7%–12.66% in the past week and 8.8%–39.85% over 30 days on sector momentum partially attributed to this legislative catalyst and related executive actions. The bill does not authorize specific dollar amounts but expands an existing VA program, creating incremental MA enrollment opportunities estimated at 5,000–15,000 lives annually.

The Improving Seniors' Timely Access to Care Act mandates electronic prior authorization for all Medicare Advantage plans by 2028, forcing a regulatory-driven health IT spending wave. Oracle (ORCL) is the clearest beneficiary as dominant EHR vendor, while major MA insurers (UNH, ELV, HUM, CVS) face mandated IT investment but gain long-term operational efficiency. The bill has strong bipartisan momentum with 68 cosponsors and an identical House companion.

HR6512, the Putting Patients First Healthcare Freedom Act, is an early-stage bill that would eliminate enhanced ACA premium subsidies, directly threatening $5-9 billion in annual premium revenue for UnitedHealth, Humana, Centene, and Molina. The bill has only 3 sponsors and 4 committee referrals, making passage unlikely in its current form, but the structural risk to the managed care sector is clearly defined. Despite the legislative risk, actual market data shows all four tickers surging over the past 30 days ($CNC +64%, $MOH +47%, $HUM +40%, $UNH +36%), indicating the market is pricing in a 'do nothing' outcome for this specific legislation.

The I CAN Act (HR1317) structurally lowers healthcare labor costs by expanding APRN scope under Medicare/Medicaid, directly benefiting managed care insurers. Real market data confirms managed-care insurers $CNC (+27.93% 7-day, +63.41% 30-day), $MOH (+10.81% 7-day, +46.26% 30-day), and $HUM (+12.05% 7-day, +39.09% 30-day) are already pricing in this regulatory tailwind. The bill is early-stage but has a companion in the Senate and executive-order tailwinds — pure-play Medicaid/Medicare insurers are the structural winners.

The Prompt and Fair Pay Act (HR4559) would eliminate the network discount advantage that generates profit margins for Medicare Advantage insurers. The bill is early-stage with low near-term passage probability, but represents an ongoing legislative risk for $UNH, $HUM, and $CVS. Humana is the most exposed pure-play MA insurer.

The Medicare Advantage Prompt Pay Act (HR5454) is early-stage legislation that would mandate MA plans to pay 95% of clean claims within 14 days (electronic in-network) or 30 days (other). This eliminates float income and increases administrative costs for MA insurers. Recent rallies in UNH (+3.3% 7-day), HUM (+12.12%), ELV (+8.12%), MOH (+10.8%), and CVS (+6.9%) appear disconnected from this structural headwind.

HR6178, introduced in November 2025 and referred to two committees, mandates no-cost lung cancer screenings and expanded tobacco cessation services under Medicaid, Medicare, and private insurance. This creates a direct revenue tailwind for diagnostic lab companies $LH and $DGX through increased test volume, and a pharmacy/PBM benefit for $CVS through mandated tobacco cessation drug coverage. Health insurers ($UNH, $HUM, $CNC, $MOH) face a neutral cost burden from the coverage mandate and prior authorization ban, with manageable MLR impact given the preventive nature of the service. The bill is early-stage with no appropriation attached.

The RAMP Act (S.3816) is an early-stage bill that would restrict MSP private litigation to group health plans only. This concentrates legal risk on major group health insurers $UNH, $CI, $HUM, and $CVS while removing liability from workers' comp, auto, and liability insurers. The bill is in committee with one cosponsor and a House companion — low near-term passage probability, but the directional impact is clear: group health insurers face higher expected litigation costs if the bill advances.

The Veterans' ACCESS Act (HR740) mandates VA referrals to private providers for eligible veterans, structurally diverting patient volume from VA facilities to commercial managed care organizations. The bill is authorization-only with no direct appropriations, but the policy mandate alone is a clear, multi-billion-dollar revenue driver for $UNH, $HUM, $MOH, $CI, and $CVS. Real market data shows these stocks already pricing in passage: 30-day gains of +34.5% ($UNH), +39.6% ($HUM), +44.6% ($MOH), +7.3% ($CI), and +15.4% ($CVS) since late March 2026.

S.4027 bans anti-steering, all-or-nothing, and most-favored-nation contract clauses that hospital systems use to block insurers from directing patients to lower-cost providers. The market has already priced in momentum: $CI +3.7%, $HUM +12.5%, $CVS +6.4% in the past 7 days. Bill is in early stages (referred to HELP Committee) with no spending authorized — the mechanism is pure regulatory leverage shift from hospitals to insurers.

HR7817, an early-stage ACA eligibility restriction bill, poses a structural downside risk to ACA marketplace insurers by reducing the subsidized enrollment pool. Despite recent stock rallies of +3.75% to +27.33% over 7 days, this bill's advance would directly pressure premium revenue for $UNH, $HUM, and $CNC. The bill is procedural (referred to committee) with no near-term passage probability, but the legislative intent signals continued Republican focus on ACA subsidy limitations.

HR7860 (Stop ACA Enrollment Fraud Act) is a procedural early-stage bill that directly addresses fraudulent ACA enrollments through mandatory SSN deduplication and agent consent. The four major publicly traded ACA insurers — UnitedHealth, Humana, Cigna, and CVS Health — all stand to benefit from reduced fraud-driven administrative costs, though the bill is still in committee and passage is uncertain.

HR7861 (Care Over Profits Act) proposes raising the minimum MLR from 80% to 85% for individual/small group health plans. The bill is early-stage, referred to committee, and faces long odds, with only one cosponsor and no companion in the Senate. Despite the bearish direct impact on insurer margins, major health insurer stocks have rallied 7-40% over the past 30 days, indicating the market is not pricing in legislative risk.

The SCAM Act (S.3674) expands civil denaturalization grounds for fraud against governmental programs, terrorist affiliation, and certain crimes. It has advanced to the Senate Legislative Calendar but authorizes zero new funding. The bill's impact is procedural and indirect, with no near-term direct market implications for publicly traded companies.

The Alternatives to PAIN Act (HR1227) is an early-stage House bill that would eliminate deductibles and lower co-pays for non-opioid pain management drugs under Medicare Part D, effective January 1, 2026. The bill has been referred to two committees with no further action since February 2025. Market impact on Part D sponsors (UNH, CVS, HUM, CI) is currently negligible because the bill is unfunded, in early legislative stages, and faces an uncertain path to enactment.

HR 2048 eliminates the 29-month cumulative waiting period for SSDI and Medicare for metastatic breast cancer patients. The bill is in early legislative stages (referred to Ways and Means), but the identical Senate companion (S3442) increases passage odds. Major health insurers ($UNH, $HUM, $CVS, $CI, $MOH, $CNC) would benefit from accelerated Medicare enrollment, bringing forward premium revenue. Over the past 7 days these tickers have rallied 3.4% to 28.5%, significantly outperforming the broad market, driven in part by sector-wide momentum around Medicare-related legislation.

The No Surprises Act Enforcement Act (HR4710) is an early-stage House bill that would increase balance billing penalties from $100/day to $10,000 per violation for health insurers. The bill has been referred to three committees and has a Senate companion (S2420). Despite the bearish legislative signal, major insurers including ELV (+7.71% 7-day) and HUM (+13.29% 7-day) have shown strong recent price momentum driven by other factors.

The Association Health Plans Act (HR2528) has advanced to the Union Calendar, expanding the addressable market for health insurers in the small group sector by allowing cross-industry associations to offer coverage. The six major health insurer stocks have shown strong positive performance over the past 7 and 30 days, with the legislative catalyst reinforcing bullish momentum in the sector.

HR 4849 permanently eliminates the 400% FPL cap on ACA premium tax credits and establishes zero-premium subsidies for incomes up to 150% FPL, driving 5-7M new exchange enrollees. Real market data shows $MOH (+49.46% 30-day) and $HUM (+46.46% 30-day) leading the sector as pure-play beneficiaries of the deepest subsidy expansion. $UNH (+41.62% 30-day) and $CVS (+19.62% 30-day) also rally but face offsetting factors from PBM margin and OBBBA repeal dynamics.

HR4773, the ACO Assignment Improvement Act of 2025, is an early-stage House bill that expands Medicare ACO beneficiary assignment to include primary care services by PAs, NPs, and CNSs starting January 2027. The bill has been referred to two committees and has a Senate companion. Managed care companies with large Medicare Advantage and ACO exposure — UnitedHealth, Humana, and CVS — are structurally positioned to benefit, though the legislative path is long and uncertain.

HR6364 (Kidd's Stuttering Act) mandates Medicaid and CHIP coverage for childhood stuttering screening and speech therapy, creating a new, guaranteed revenue stream for managed care organizations and speech therapy providers. The bill is in early stage (referred to committee) with 12 cosponsors. Real market data shows UNH, ELV, and HUM all up 32-46% in the last 30 days, though this is likely driven by broader sector momentum rather than this specific bill at this stage.

HR 7164 (Capping Costs for Consumers Act) proposes expanding CSR subsidies to gold-level coverage on exchanges starting 2028. The bill is early-stage, referred to two committees with a single Democratic sponsor. For the major insurers with exchange exposure (UNH, CVS/CI, HUM), the mechanism increases government subsidy payments, reduces churn, and improves enrollment retention. Real market data shows significant recent upward momentum in the managed care sector: UNH up 41.6% in 30 days, HUM up 46.5%, reflecting broader sentiment tailwinds.

Medicare for All Act (HR3069) would eliminate private health insurance, replacing it with a single-payer federal program. The bill is in early legislative stages (referred to 7 committees, 114 cosponsors, all Democrats). Recent real market data shows private insurers rallied 20-70% over the past 30 days on unrelated factors (likely earnings or regulatory clarity), not legislative risk. A structural existential threat exists for managed care companies if this bill advanced to law — but current legislative probability near zero given Republican House control and early-stage procedural status.

The Medical Nutrition Therapy Act of 2026 structurally expands Medicare Part B to cover nutrition counseling for obesity, cancer, HIV/AIDS, and eating disorders — a direct benefit expansion for MA insurers Humana, UnitedHealth, Centene, and CVS Health, which can integrate these services to manage chronic disease costs. The bill is early-stage (referred to Senate Finance, 2 co-sponsors), but real market data shows the affected tickers have experienced 19-70% 30-day gains, reflecting broader sector momentum.